Smoking-associated Downregulation of FILIP1L Enhances Lung Adenocarcinoma Progression Through Mucin Production, Inflammation, and Fibrosis.
Journal
Cancer research communications
ISSN: 2767-9764
Titre abrégé: Cancer Res Commun
Pays: United States
ID NLM: 9918281580506676
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
09
06
2022
revised:
19
07
2022
accepted:
07
09
2022
entrez:
2
3
2023
pubmed:
3
3
2023
medline:
3
3
2023
Statut:
epublish
Résumé
Lung adenocarcinoma (LUAD) is the major subtype in lung cancer, and cigarette smoking is essentially linked to its pathogenesis. We show that downregulation of Filamin A interacting protein 1-like (FILIP1L) is a driver of LUAD progression. Cigarette smoking causes its downregulation by promoter methylation in LUAD. Loss of FILIP1L increases xenograft growth, and, in lung-specific knockout mice, induces lung adenoma formation and mucin secretion. In syngeneic allograft tumors, reduction of FILIP1L and subsequent increase in its binding partner, prefoldin 1 (PFDN1) increases mucin secretion, proliferation, inflammation, and fibrosis. Importantly, from the RNA-sequencing analysis of these tumors, reduction of FILIP1L is associated with upregulated Wnt/β-catenin signaling, which has been implicated in proliferation of cancer cells as well as inflammation and fibrosis within the tumor microenvironment. Overall, these findings suggest that down-regulation of FILIP1L is clinically relevant in LUAD, and warrant further efforts to evaluate pharmacologic regimens that either directly or indirectly restore FILIP1L-mediated gene regulation for the treatment of these neoplasms. This study identifies FILIP1L as a tumor suppressor in LUADs and demonstrates that downregulation of FILIP1L is a clinically relevant event in the pathogenesis and clinical course of these neoplasms.
Identifiants
pubmed: 36860703
doi: 10.1158/2767-9764.CRC-22-0233
pii: CRC-22-0233
pmc: PMC9973389
doi:
Substances chimiques
Mucins
0
FILIP1L protein, human
0
Intracellular Signaling Peptides and Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Pagination
1197-1213Subventions
Organisme : NCI NIH HHS
ID : P30 CA072720
Pays : United States
Informations de copyright
© 2022 The Authors; Published by the American Association for Cancer Research.
Références
Cancer Sci. 2018 Jun;109(6):2063-2073
pubmed: 29701925
Oncogene. 2018 Aug;37(33):4518-4533
pubmed: 29743597
J Thorac Oncol. 2015 Jan;10(1):19-27
pubmed: 25319180
Mol Cancer Res. 2011 Aug;9(8):1126-38
pubmed: 21693594
Oncogene. 2019 Sep;38(36):6354-6369
pubmed: 31320708
Nat Commun. 2017 Feb 01;8:14381
pubmed: 28146145
Nat Commun. 2018 Dec 18;9(1):5363
pubmed: 30560893
BMC Cancer. 2021 Jan 23;21(1):96
pubmed: 33485313
JTO Clin Res Rep. 2021 May 08;2(7):100181
pubmed: 34790904
Oncotarget. 2014 Jun 15;5(11):3636-50
pubmed: 25004243
J Biol Chem. 2002 Oct 11;277(41):38239-44
pubmed: 12154096
Cancer Discov. 2014 Apr;4(4):415-22
pubmed: 24469108
Carcinogenesis. 2021 Dec 31;42(12):1461-1474
pubmed: 34487521
BMC Cancer. 2019 Aug 20;19(1):824
pubmed: 31429720
Cancer Metastasis Rev. 2019 Jun;38(1-2):223-236
pubmed: 30618016
Front Oncol. 2018 Jun 04;8:195
pubmed: 29915721
Immunol Res. 2007;38(1-3):112-21
pubmed: 17917016
Mol Oncol. 2016 Feb;10(2):224-39
pubmed: 26526617
J Natl Cancer Inst. 2013 Dec 18;105(24):1871-80
pubmed: 24249745
Int J Cancer. 2014 Jul 1;135(1):48-60
pubmed: 24327474
MethodsX. 2019 Oct 18;6:2468-2475
pubmed: 31720237
Cancer Res. 2008 Sep 15;68(18):7332-41
pubmed: 18794120
J Cell Mol Med. 2020 Jun;24(12):6804-6821
pubmed: 32352211
Clin Epigenetics. 2021 Jun 9;13(1):126
pubmed: 34108011
Front Cell Dev Biol. 2022 Jan 17;9:816214
pubmed: 35111762
Int J Mol Med. 2018 Aug;42(2):713-725
pubmed: 29786110
Semin Cell Dev Biol. 2017 Apr;64:73-78
pubmed: 27569189
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Antioxid Redox Signal. 2019 Mar 10;30(8):1124-1143
pubmed: 29634348
Nature. 2017 May 18;545(7654):355-359
pubmed: 28489818
J Immunol. 2004 Apr 1;172(7):4510-9
pubmed: 15034068
Dev Cell. 2014 Dec 8;31(5):525-38
pubmed: 25490264
Cancer Res. 2021 Nov 1;81(21):5523-5539
pubmed: 34417201
Front Immunol. 2018 Mar 20;9:563
pubmed: 29662489
Nat Med. 2015 Aug;21(8):938-945
pubmed: 26193342
Pediatr Res. 2021 Apr;89(5):1126-1135
pubmed: 32303051
J Innate Immun. 2017;9(3):281-299
pubmed: 28052300
J Pathol. 2014 May;233(1):7-17
pubmed: 24258247
Sci Rep. 2015 Mar 03;5:8649
pubmed: 25733373
Science. 2016 Nov 4;354(6312):618-622
pubmed: 27811275
Proc Natl Acad Sci U S A. 2013 Aug 27;110(35):14219-24
pubmed: 23940311
Cancer Cell. 2017 Sep 11;32(3):360-376.e6
pubmed: 28898697
Onco Targets Ther. 2020 Apr 16;13:3177-3186
pubmed: 32368077
EBioMedicine. 2021 May;67:103383
pubmed: 34000624
J Thorac Dis. 2017 Oct;9(10):4017-4026
pubmed: 29268412
CA Cancer J Clin. 2018 Jan;68(1):31-54
pubmed: 29160902
Nat Protoc. 2009;4(7):1064-72
pubmed: 19561589
Biosci Rep. 2020 Feb 28;40(2):
pubmed: 31957800
J Urol. 2013 Jan;189(1):329-35
pubmed: 23174249
J Cell Biol. 2005 Feb 14;168(4):633-42
pubmed: 15716380
J Leukoc Biol. 2013 Oct;94(4):585-94
pubmed: 23543767
JCI Insight. 2019 Dec 19;4(24):
pubmed: 31852841
Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1729-51
pubmed: 24962838
Int J Cancer. 1996 Dec 20;69(6):457-65
pubmed: 8980247
Genome Res. 2012 Jul;22(7):1197-211
pubmed: 22613842
Cancer Res. 2001 Aug 15;61(16):6050-4
pubmed: 11507052
Chest. 2018 Jul;154(1):169-176
pubmed: 29170036
Cancers (Basel). 2020 Apr 24;12(4):
pubmed: 32344577
Oncotarget. 2016 Nov 1;7(44):72229-72241
pubmed: 27750216
Cell. 2019 Jul 11;178(2):330-345.e22
pubmed: 31257027
PLoS One. 2013 Dec 05;8(12):e82620
pubmed: 24340050
Cell. 2002 Mar 22;108(6):837-47
pubmed: 11955436
Nature. 2020 Feb;578(7794):266-272
pubmed: 31996850
Cancer Res. 2006 Jul 15;66(14):7024-31
pubmed: 16849547
EMBO Mol Med. 2017 Apr;9(4):462-481
pubmed: 28255028
Oncogene. 1996 Feb 1;12(3):555-62
pubmed: 8637712
Genes Dev. 2004 Nov 15;18(22):2718-23
pubmed: 15545629
Clin Lung Cancer. 2017 Jul;18(4):e273-e281
pubmed: 28065467
Front Immunol. 2018 Nov 19;9:2625
pubmed: 30510554
Mol Aspects Med. 2020 Dec;76:100859
pubmed: 32386845
J Clin Invest. 2013 Mar;123(3):1241-61
pubmed: 23426183
J Clin Med. 2019 Sep 11;8(9):
pubmed: 31514468
Gastroenterology. 2005 Jul;129(1):285-302
pubmed: 16012954
Cancers (Basel). 2018 Jul 27;10(8):
pubmed: 30060526
Nat Immunol. 2007 Sep;8(9):931-41
pubmed: 17694059
Oncogene. 2010 Apr 1;29(13):1929-40
pubmed: 20062083
Curr Genomics. 2021 Feb;22(2):79-87
pubmed: 34220295
Cancers (Basel). 2022 Feb 15;14(4):
pubmed: 35205708
Front Oncol. 2020 Sep 11;10:1766
pubmed: 33014869
J Clin Invest. 2012 Dec;122(12):4388-400
pubmed: 23143308
Oncotarget. 2016 Nov 22;7(47):77052-77070
pubmed: 27776341
Med Oncol. 2015 Dec;32(12):264
pubmed: 26553318
Carcinogenesis. 2019 Apr 29;40(2):324-334
pubmed: 30698677
Nat Commun. 2017 Dec 21;8(1):2238
pubmed: 29269828
Life Sci. 2021 Dec 1;286:120061
pubmed: 34666037
Ann Transl Med. 2020 May;8(10):651
pubmed: 32566588
Oncogene. 2017 Feb 16;36(7):885-898
pubmed: 27694898
Sci Rep. 2021 Dec 2;11(1):23337
pubmed: 34857857
Am J Physiol Lung Cell Mol Physiol. 2017 Mar 1;312(3):L334-L347
pubmed: 28011616
Int J Mol Sci. 2019 Jan 30;20(3):
pubmed: 30704051
Am J Pathol. 1999 Oct;155(4):1033-8
pubmed: 10514384
PLoS One. 2019 Nov 25;14(11):e0225755
pubmed: 31765425
Oncogene. 2010 Jun 24;29(25):3650-64
pubmed: 20440268
Genome Biol. 2006;7(10):R100
pubmed: 17076895